Pfizer And BioNTech Claim COVID-19 Vaccine Success
Interim Analysis Finds Vaccine 90% Effective, EUA Filing Expected Late November
The companies look to have secured a better than expected 90% efficacy level, but will await safety data before filing later this month.
You may also be interested in...
Coronavirus Update: CureVac's EU Vaccine Deal, J&J's New Vaccine Study, BioNTech/Fosun Get China Go-Ahead
CureVac seals EU Deal for 405 million doses of CVnCoV, a second Phase III trial for J&J’s COVID-19 vaccine starts, and BioNTech, Fosun get OK for China vaccine trial.
The company's Phase III COVID-19 vaccine trial has reached the needed safety data required for filing an emergency use authorization with the FDA, Bourla confirmed at the Stat Summit.
FTC warns 20 firms selling products or services promising to prevent or treat COVID-19, including three clinics saying peptides help boost the effectiveness of a vaccine. NJ business promoting collodial silver to prevent or treat novel coronavirus infection shut down in a DoJ complaint after failing to comply with regulatory agencies' warning.